Drug-releasing system of biodegradable polymer type
A method for producing compression-melt molded product using polylactic acid powder is described. The method comprises the steps of: 1) heat-melting polylactic acid having a weight-average molecular weight of 3,000-40,000 at 140-220° C., 2) allowing the melted polylactic acid to cool down to solidify at an ordinary or a lower temperature, 3) pulverizing the solidified polylactic acid at an ordinary temperature into powder, and 4) compressing the powder or a mixture powder prepared by addition of another ingredient, e.g., a biologically active compound, to the carrier powder in a mold at an ordinary temperature to cause the polylactic acid to melt into a molded product of a predetermined shape.
1. A method for production of a biodegradable polymer-based drug releasing system consisting of the steps of:
1) heat-melting polylactic acid having a weight-average molecular weight of 3,000-40,000 at 140-220° C.,
2) allowing the melted polylactic acid prepared in step (1) to cool down to solidify at a temperature of about 20° C. to 30° C.,
3) pulverizing the solidified polylactic acid prepared in step (2) into powder at about 20° C. to 30° C., and
4) mixing the powder prepared in step (3) with a powder of a biologically active compound at about 20° C. to 30° C. and compressing thus prepared mixture powder in a mold at about 20° C. to 30° C. to cause the polylactic acid to melt into a molded product of a predetermined shape.
2. The method of claim 1 , wherein the polylactic acid is DL-polylactic acid, D-polylactic acid or L-polylactic acid.
3. The method of claim 1 , wherein the polylactic acid is DL-polylactic acid and the weight-average molecular weight of the polylactic acid is 8,000-30,000.
4. The method of claim 1 , wherein the polylactic acid is D-polylactic acid or L-polylactic acid and the weight-average molecular weight of the polylactic acid is 3,000-30,000.
5. The method of claim 1 , wherein the weight ratio of the biologically active compound to polylactic acid is not more than 2:5 in the mixture powder.
6. The method of claim 1 , wherein the mold has a cylindrical inner surface and the mixture powder is compressed in the direction of the axis of the mold.
7. The method of claim 1 , wherein the biologically active compound is selected from the group consisting of antibiotics, antimicrobials, antivirals, vascularization suppressors, anti-glaucoma agents, anti-cataract agents, anticancer agents and vaccine antigens.
8. The method of claim 1 , wherein the biologically active compound is a physiologically active peptide.